Journal
CNS NEUROSCIENCE & THERAPEUTICS
Volume 19, Issue 5, Pages 302-306Publisher
WILEY-BLACKWELL
DOI: 10.1111/cns.12101
Keywords
Aminopyridines; Fampridine; Multiple sclerosis; Walking
Categories
Funding
- MSM [0021620849]
- Biogen Idec
- Novartis
- Ministry of Health for MS research
- [PRVOUK-P26/LF1/4]
Ask authors/readers for more resources
Prolonged-release fampridine (fampridine PR) is a potassium channel blocker that improves conductivity of signal on demyelinated axons in central nervous system. Fampridine PR has been approved to improve speed of walking in patients with multiple sclerosis. This statement provides a brief summary of data on fampridine PR and recommendations on practical use of the medication in clinical practice, prediction, and evaluation of response to treatment and patient management.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available